(1995; 152 pages) [French] [Spanish]
Group: luminal amoebicide
Tablet 500 mg of diloxanide furoate
An amoebicide that is active only against organisms in the gastrointestinal contents. Less than 10% of an oral dose is excreted in the faeces, but sufficient amounts reach the colonic lumen to eradicate intraluminal forms of E. histolytica. The remainder is hydrolysed within the intestinal mucosa as it is absorbed and subsequently excreted in the urine as the glucuronide. Concentrations attained in tissues, including the intestinal mucosa, are subtherapeutic.
• treatment of asymptomatic carriers in non-endemic areas
• eradication of residual amoebae in the colonic lumen following treatment of invasive disease with antiamoebic drugs.
Dosage and administration
Adults: 500 mg three times daily for 10 days.
Children: 20 mg/kg daily in three divided doses for 10 days.
Treatment is regarded as successful if stools remain free of E. histolytica for one month. Several specimens should be examined in evaluating the response to treatment.
Contraindications and precautions
Diloxanide appears to be essentially nontoxic and is well suited to outpatient use.
Use in pregnancy
No untoward effects have been demonstrated but treatment is best deferred, when possible, until after the first trimester of pregnancy.
Mild gastrointestinal symptoms, particularly flatulence, may be troublesome. Pruritus and urticaria can also occur.
Tablets should be kept in well-closed containers, protected from light.